

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

OVERSEAS REGULATORY ANNOUNCEMENT LEGEND BIOTECH ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”) pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Reference is made to the announcement of the Company dated September 20, 2024, in relation to the notice of the 2024 annual general meeting of Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States.

On October 21, 2024 (New York time), Legend Biotech has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) in relation to the voting results of the 2024 annual general meeting of Legend Biotech (the “**Results**”). For details, please refer to the attached Results. The attached Results is the full Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000119312524240395/0001193125-24-240395-index.html>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Jiange Meng
Chairman and Executive Director

Hong Kong, October 22, 2024

*As at the date of this announcement, the executive Directors are Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Mr. Jiange Meng (“**Mr. Robin Meng**”), Ms. Ye Wang (“**Ms. Sally Wang**”) and Dr. Li Zhu; the non-executive Directors are Dr. Luquan Wang (“**Dr. Larry Wang**”) and Dr. Ross Allen Grossman; and the independent non-executive Directors are Mr. Zumian Dai (“**Mr. Edward Dai**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Mr. Yiu Leung Andy Cheung, Dr. Chenyang Shi (“**Dr. Victor Shi**”) and Dr. Alphonse Galdes.*

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

Date of Report: October 21, 2024

Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)

**2101 Cottontail Lane
Somerset, New Jersey 08873**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K on paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K on paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On October 21, 2024, Legend Biotech Corporation (the “Company”) held its 2024 Annual General Meeting of Shareholders (the “Meeting”). The voting results are attached hereto as Exhibit 99.1.

This report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-257625, 333-272222 and 333-278050) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

EXHIBITS

Exhibit 99.1 — Voting Results of Annual General Meeting

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEGEND BIOTECH CORPORATION

Date: October 21, 2024

By: /s/ Ying Huang

Name: Ying Huang, Ph.D.

Title: Chief Executive Officer

Voting Results of 2024 Annual General Meeting

At Legend Biotech Corporation's (the "Company") annual general meeting of shareholders held on October 21, 2024 (the "AGM"), the Company's shareholders:

- received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2023;
- ratified the appointment of Ernst & Young LLP as the Company's independent auditor for the fiscal year ending December 31, 2024;
- re-elected each of Ms. Ye Wang, Dr. Darren Xiaohui Ji, Dr. Ying Huang and Mr. Tomas Heyman to serve as a Class I director for a three-year term;
- approved the amendment and restatement of the Company's 2020 Restricted Shares Plan to increase the aggregate number of ordinary shares reserved for issuance by 15,000,000 ordinary shares; and
- authorized each of the directors and officers of the Company to take any and every action that might be necessary to effect the forgoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.

A total of approximately 351,102,656 ordinary shares, including those underlying ADSs, representing approximately 95.3% of the ordinary shares issued and outstanding as of September 17, 2024, the record date, were present in person or by proxy at the AGM. The results of the votes are as follows:

<u>Resolutions</u>	<u>For</u>		<u>Against</u>		<u>Abstain</u>	
	<u>Votes</u>	<u>%</u>	<u>Votes</u>	<u>%</u>	<u>Votes</u>	<u>%</u>
Reception of Audited Financial Statements	351,026,682	95.238%	35,060	0.010%	40,914	0.011%
Ratification of appointment of Ernst & Young LLP as Independent Auditor for Fiscal Year 2024	351,070,748	95.250%	3,276	0.001%	28,632	0.008%
Election of Directors						
Ye Wang (Class I)	254,083,338	68.936%	96,987,136	26.314%	32,182	0.009%
Dr. Darren Xiahui Ji (Class I)	344,087,858	93.356%	6,982,614	1.894%	32,184	0.009%
Dr. Ying Huang (Class I)	350,256,394	95.029%	814,082	0.221%	32,180	0.009%
Tomas Heyman (Class I)	344,761,778	93.539%	6,307,538	1.711%	33,340	0.009%
Amendment and Restatement of 2020 Restricted Shares Plan	347,474,014	94.275%	3,601,752	0.977%	26,890	0.007%
Authorization of Directors and Officers	350,780,616	95.172%	191,268	0.052%	130,772	0.035%